Word from the Chair
In the recently released Office of the Chief Coroner Report of 2009-2011, Chief Coroner Andrew McCallum notes an increase in deaths resulting from opioid use. While the graph provided in the report does not show exact figures, it appears that:
-
methadone-related deaths increased from around 60 in 2009 to over 100 in 2011.
-
Deaths related to fentanyl use increased steadily starting in 2006 to a high of 100 deaths in 2011.
-
Deaths due to oxycodone use decreased very slightly in 2011 from around 170 to around 160, although,
-
deaths from hydromorphone increased from around 30 to 40.
-
Deaths related to heroine, codeine and morphine were more or less steady from 2010-11
It is of great concern to care providers that, despite their best efforts, death due to drug use remains an issue. There is, unfortunately, nothing in this report to indicate whether the methadone deaths occurred in patients who were in methadone programs, or whether the deaths were of methadone-naïve patients who used diverted methadone. We might surmise that as oxycodone use has decreased due to decreased availability, the use of other opioids has increased resulting in more deaths.
This serves as a reminder to prescribers to carefully review the section of the
MMT Program Standards and Clinical Guidelines relating to initiating patients on Methadone (section 6) and take-home doses (section 8). The Methadone Committee frequently sees, even in good practices, occasional deviations from the standards with respect to how frequently methadone doses are increased and the rate at which the dose is increased in the initiation phase, as well as issues with patients who are given carries despite continued, problematic drug use and the frequency with which carries are increased.
I urge you to continually review the Standards document and make adjustments to your practice accordingly. Use your colleagues as a resource to problem-solve when faced with difficult situations. Your goal should always be to ensure the safety of your patients, and, ongoing quality improvement efforts will assist in that goal. With that in mind, please review this issue’s
Methadone Q&A regarding concurrent use of methadone and Wellbutrin.
The College’s annual Methadone
Prescribers Conference will be held on
November 15, 2013 at the
Allstream Centre in
Toronto. Proposed topics include:
• Methadone and pain
• Methadone and aging
• UDS monitoring
• Motivational interviewing
• Naloxone training
If you have suggestions for break-out sessions/speakers, please contact
Maureen Gans.
Methadone Q&A
Q. I have heard that Wellbutrin is abused in the methadone population of patients. I have a stable patient on methadone and I am also prescribing Wellbutrin for depression. How do I manage this patient?
A. Abuse of Wellbutrin by both injection and snorting has been widely reported. There is a growing number of Wellbutrin-related deaths secondary to abuse. Patients who abuse Wellbutrin report a euphoric effect similar to that provided by cocaine. The Methadone Committee recommends avoiding Wellbutrin, or changing to an antidepressant with less abuse potential (e.g. SSRIs) in clinically unstable patients who have ongoing drug use, particularly the cocaine-abusing population. Prescribers should weigh the risks and benefits of using Wellbutin in stable drug-free patients with a dual diagnosis of depression who have benefited from its therapeutic antidepressant effect.
If the prescriber chooses to maintain Wellbutrin in the drug-free population, it is important to screen for signs and symptoms of Wellbutrin abuse (i.e., track marks, early refills, lost medications, etc). It is important to prescribe the Wellbutrin in a controlled fashion (i.e., daily to weekly and dispensed with the carries).
Important Message to
All Methadone Prescribers and their Clinic Staff
from the CPSO Methadone Committee
The CPSO Methadone Program will no longer provide verbal approvals for same day starts unless the patient is pregnant. According to G5.10 on page 30 of the Guidelines:
The MMT physician may initiate MMT prior to receiving confirmation from CPSO if:
-
The patient meets the DSM4 criteria for opioid dependency
-
The initial UDS verifies the self- report of the patient and is not positive for methadone
-
The physician feels a concern that a delay in initiation will cause the patient undue harm or lose the patient in retention.
If the initial UDS is positive for methadone, then the patient should not be initiated on MMT, and should be asked to return in a few days pending CPSO approval, as no verbal approval will be provided.
MMT prescribers should be aware that many patients seeking methadone treatment do not require to be started on the same day of the initial presentation, and a follow-up visit can be arranged.
Patient Forum highlights issues of particular interest to methadone patients.
Issue 34, March 2013
Methadone and Aging
I wrote this essay because as a methadone client and a senior I am interested in the topic and thought you might be too ...
read it here
View Archives
Please send your comments and feedback to:
qmdnewsletters@cpso.on.ca
Visit our website at:
www.cpso.on.ca